-
Gene Therapy's $250 million acquisition could break through existing CRISPR...
Time of Update: 2021-01-05
With the help of a technology platform, the company uses a new type of OMNI™ nuclease to optimize each target gene to meet the three requirements for successful high-precision gene editing: allephase gene specificity, high activity, and no "off-target effect", while maintaining the efficiency of gene editing.
-
China Resources Shuanghe acquired a 38.75% stake in Dongying Tiandong Pharmaceuticals
Time of Update: 2021-01-05
On December 17, China Resources Shuanghe announced that, in accordance with the company's overall strategic plan, in order to further enrich the cardiovascular anticoagulant field products, access to anticoagulant field technology platform, the company used its own funds to acquire a 38.75 percent stake in Dongying Tiandong Pharmaceutical Co., Ltd., the purchase price of 341 million yuan.
-
Liquid biopsy company announces new number of DETECT research projects...
Time of Update: 2021-01-05
DETECT III program is by far the largest screening analysis, taking into account the added value of CTC HER2 plus over-expression in a female HER2-negative breast cancer primary tumor biopsy to optimize patient management.
-
The new drug for leukemia, Gilantini, is listed in China, where Astellas has chosen to work with Baiyang
Time of Update: 2021-01-05
Text . . Linan accelerates priority review and approval of innovative drugs, establishes a list of new drugs that are clinically urgently needed abroad... In recent years, with the reform of China's
-
JEM: Revealing the effects of aging on hematopoietic stem cell function
Time of Update: 2021-01-04
more detailed analysis may find that aging studies focusing on hematopoietic stem cells, which irreversibly affect the function of older HSC, have been active in mice with bone marrow transplant models.
-
Science: The most "safe" gene therapy vector does not appear to be safe, with haemophilia patients suffering from liver cancer after treatment
Time of Update: 2021-01-01
2019, uniQure shared clinical data from Phase 2 of the therapy at the 27th International Society for Thrombosis and Hemostation (ISTH), showing that three patients had 54 percent of their normal FIX activity after 36 weeks of treatment, with an average of 45 percent of normal.
-
Blood: Genome and transcriptomic characteristics transformed by Richter of chronic lymphocytic leukemia
Time of Update: 2021-01-01
study process showed that in tissue-RS, gene mutations in low-risk CLL-driven and DNA Damage Response (DDR) pathways were rich.
SNV, InDel, and CNA in patients with Richter syndrome, the researchers found in tissue-RS a kataegis associated with AND unrelated to AIDS that affects the regulatory regions of key immunomodulation genes.
-
NEJM: Aza cytosine oral agent is used for maintenance therapy in patients with acute myeloid leukemia in old age after chemotherapy remission
Time of Update: 2021-01-01
Acute myeloid leukemia (AML) is a common blood tumor in the elderly, with approximately 40-60% of AML patients over 60 years of age achieving complete remission through standard induced chemotherapy, but most patients (80-90%) subsequently relapse, resulting in a decrease in overall survival.
-
Lancet Neurology: Blood phosphorylation tau-181, as a biomarker of Alzheimer's disease, has the hope of being incorporated into clinical practice with a rapid screening trial
Time of Update: 2021-01-01
the purpose of this paper is to assess whether p-tau181 in the blood can be used as a biomarker of Alzheimer's disease and to predict cognitive decline and hema atrophy.
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
-
Domestic autonomous CAR-T therapy was included in the breakthrough treatment varieties
Time of Update: 2021-01-01
According to the official website of the Drug Audit Center of the State Drug Administration, the co-source biological CAR-T cell therapy product CNCT19 cell injection (anti-CD19 chime antigen-liked antigen t-cell injection) was approved to be included in the "breakthrough treatment drug" (CDE acceptance number: CXSL1800106), the intended indication is relapsed or refractory acute lymphoblastic leukemia.
-
Blood: Notch signal promotes the development of chronic lymphocytic leukemia
Time of Update: 2021-01-01
Center point: IgH.TE'SLL mouse model can relifully reproduce the pathological characteristics of human CLL, Notch signal promotes the occurrence of CLL disease, promotes cell proliferation and CLL disease progression.
-
"China's lymphoma patients throughout the management of quality control standards" issued to promote the standardization of lymphoma diagnosis and treatment
Time of Update: 2021-01-01
In order to implement the State Council's Action Plan for Further Improving Medical Services, promote the landing of the "Healthy China 2030 Plan" and increase the overall cancer survival rate by 15%
-
N Engl J Med: First time! CRISPR-Cas9 technology can effectively treat sickle cell anemia and β-thalassemia in human trials
Time of Update: 2020-12-31
December 5, 2020, researchers at the Sarsh Cannon Institute, Boston University School of Medicine, and others published an article in NEJM entitled "CRISPR-Cas Gene9 Editing for Sickle Cell Disease and β-Thalassemia", which showed that using CRISPR-Cas9 technology to edit the body CD34 plus cells, increase fetal hemoglobin expression, and effectively treat TDT and SCD.
-
J Clin Oncol: Children's ALL is the most appropriate myelin solution before allo-HSCT
Time of Update: 2020-12-31
The study was an international multi-center, open-label, randomized Phase III non-inefficient trial that recruited patients aged 18 and under who had HSCT between the ages of 4 and 21 who had received complete remission before HSCT, and who were randomly treated with TBI (12 Gy) plus etoposides vs.
-
Blood: The efficacy of atropal monoantigen for the initial treatment of aaIPI≥1 in DLBCL patients was no better than lytocyclic monoantigen
Time of Update: 2020-12-25
DLBCL patients who met the transplant criteria (18-60 years old) and were treated with an untreated age-adjusted International Prognostic Index (aaIPI) ≥1 were randomly divided into two groups (1:1) to receive atropal or lysoxi monoantigen therapy, respectively.
-
Blood: Effective disease risk index for allogeneic hematocyte transplantation in children with blood tumors
Time of Update: 2020-12-25
the survival and total survival of leukemia was divided into four risk groups for AML patients, depending on age, cytogenetic risk, and disease status, including the lowest residual disease status at the time of transplantation.
-
Lancet oncol: Papiss is given the efficacy and safety of boronitzomi to treat recurring/refracilable multiple myeloma
Time of Update: 2020-12-25
Pabissat 20mg 3 times/week with subsurfed injection boron tazomethami combined application is safer than in the past the dose and intravenous giving boron tezometri is better, suggesting that subdermi subsoil drug can also improve the tolerance of Papiss and his joint program.
-
For the treatment of acute lymphoblastic leukemia, co-sourced biological CAR-T therapy is intended to be included in the breakthrough treatment varieties
Time of Update: 2020-12-25
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
-
Clin Cancer Res: JAK1 inhibitor Itacitinib is effective in preventing cytokine release syndrome caused by CAR T cell therapy
Time of Update: 2020-12-25
study, the researchers analyzed the effects of blocking JAK signaling path pathps on CAR T cell proliferation, anti-tumor activity, and cytokine levels.
, the anti-tumor activity of CD19-CAR T cells injected into the mouse decreased after oral itinib treatment of the immunodeficiency CD19 plus tumor mouse model.
-
Masimo SpHb® noninvasional continuous hemoglobin monitoring as part of blood management in children can reduce ICU retention time and postoperative blood transfusions
Time of Update: 2020-12-25
Masino (NASDAQ: MASI) recently released the results of a summary of the latest report in Euroanaesthesia 2020: Dr. Saraçoğlu of the University of Marmara in Istanbul, Turkey, and colleagues investigated the effectiveness of Massimo's noninvasive continuous hemoglobin monitoring SpHb® as a component of blood transfusion management in children undergoing major surgery1.
